AR120719A1 - Anticuerpos glicosilados contra el receptor del factor de crecimiento i similar a la insulina y sus usos - Google Patents

Anticuerpos glicosilados contra el receptor del factor de crecimiento i similar a la insulina y sus usos

Info

Publication number
AR120719A1
AR120719A1 ARP200103440A ARP200103440A AR120719A1 AR 120719 A1 AR120719 A1 AR 120719A1 AR P200103440 A ARP200103440 A AR P200103440A AR P200103440 A ARP200103440 A AR P200103440A AR 120719 A1 AR120719 A1 AR 120719A1
Authority
AR
Argentina
Prior art keywords
insulin
receptor
growth factor
antibodies against
glycosylated antibodies
Prior art date
Application number
ARP200103440A
Other languages
English (en)
Inventor
Anne Odonnell
Patrick Michael Jennings
Edel Mullen
Original Assignee
Horizon Therapeutics Ireland Designated Activity Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Therapeutics Ireland Designated Activity Company filed Critical Horizon Therapeutics Ireland Designated Activity Company
Publication of AR120719A1 publication Critical patent/AR120719A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Una composición que comprende una pluralidad de anticuerpos monoclonales recombinantes (mAb), de secuencia idéntica, que se unen al receptor del factor de crecimiento I similar a la insulina (IGF-IR), en la que cada mAb comprende dominios constantes de cadena pesada de IgG1 o IgG3 humana glicosilados con una cadena de azúcar en Asn297, donde dichos mAb se caracterizan porque el 96 - 98% de las cadenas de azúcar tienen al menos un grupo fucosilo y cada cadena de azúcar tiene de aproximadamente 1 - 3% de derivados del ácido siálico, 1% o menos de a-1,3-galactosa y aproximadamente 35 - 40% de galactosa y usos de esta.
ARP200103440A 2019-12-10 2020-12-10 Anticuerpos glicosilados contra el receptor del factor de crecimiento i similar a la insulina y sus usos AR120719A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962946230P 2019-12-10 2019-12-10

Publications (1)

Publication Number Publication Date
AR120719A1 true AR120719A1 (es) 2022-03-09

Family

ID=76330772

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200103440A AR120719A1 (es) 2019-12-10 2020-12-10 Anticuerpos glicosilados contra el receptor del factor de crecimiento i similar a la insulina y sus usos

Country Status (2)

Country Link
AR (1) AR120719A1 (es)
WO (1) WO2021119234A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021243014A1 (en) * 2020-05-28 2021-12-02 Horizon Therapeutics Ireland Dac Methods for the treatment of idiopathic orbital inflammation and related conditions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080014203A1 (en) * 2006-04-11 2008-01-17 Silke Hansen Antibodies against insulin-like growth factor I receptor and uses thereof

Also Published As

Publication number Publication date
WO2021119234A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
BR112017019978A2 (pt) anticorpo ou um fragmento de ligação com antígeno, conjugado, receptor de antígeno, cadeia, conjugado de cadeia, proteína de fusão, célula t, polinucleotídeo, vetor, célula ex vivo, método para produzir uma cadeia, método para produzir um anticorpo, composição farmacêutica, método para tratamento de câncer, glicopeptídeo, método para gerar um anticorpo
PE20231067A1 (es) Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos
AR110017A1 (es) Anticuerpos de pd-1 y usos de estos
CL2023001076A1 (es) Anticuerpos monoclonales anti-ccr8 y sus usos.
PE20190975A1 (es) Novela cd47 anticuerpos monoclonales y sus usos
CL2022002555A1 (es) Anticuerpos anti-ccr8 para el tratamiento del cáncer
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
AR120563A1 (es) Receptores de antígeno quimérico cd19 y cd22 y sus usos
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
AR095115A1 (es) Anticuerpos que comprenden dominios constantes quiméricos
MX2019013132A (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
BRPI0821168B8 (pt) anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma
MX2017006323A (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
PE20170782A1 (es) Anticuerpos frente a cd73 y usos de los mismos
UY37698A (es) Proteínas de unión a antígenos trem2 y usos de estas
AR071698A1 (es) Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos
CL2013003634A1 (es) Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso
EA201792221A1 (ru) Антитела против сортилина и способы их применения
PE20091196A1 (es) Anticuerpos contra el vegf completamente humano, composiciones y metodos
ECSP066681A (es) Formas sólidas de anticuerpos anti-egfr
AR069130A1 (es) Moleculas de enlace de la opsonina principal del complemento (c3b) y metodos para modular el componente de complemento
PE20180249A1 (es) Anticuerpos neutralizadores anti-ccl20
PE20081186A1 (es) Metodos y composiciones para el tratamiento de enfermedades alergicas
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion

Legal Events

Date Code Title Description
FB Suspension of granting procedure